



CORRECTION

Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment

Francesco Oddone · James Kirwan · Fernando Lopez-Lopez · Marina Zimina · Claudia Fassari · Gábor Holló on behalf of The VISIONARY Study Group

Published online: June 22, 2022
© Springer Healthcare Ltd., part of Springer Nature 2022

Correction to: Adv Ther
<https://doi.org/10.1007/s12325-022-02166-6>

The authors would like to acknowledge missing data for all prior latanoprost users as a whole. The following sentence has been added to the manuscript (page 8, first paragraph):

The original article can be found online at <https://doi.org/10.1007/s12325-022-02166-6>.

F. Oddone (✉)
Glaucoma Unit, IRCSS-Fondazione Bietti, Rome, Italy
e-mail: oddonef@gmail.com

J. Kirwan
Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Portsmouth, UK

F. Lopez-Lopez
Instituto Oftalmologico Gomez-Ulla, Calle Maruxa Mallo 3 Santiago de Compostela, Galicia, Spain

M. Zimina
LLC Vzglyad, Leningradskaya, Chita, Russia

C. Fassari
Santen SA, Geneva, Switzerland

G. Holló
Tutkimusz Ltd, Solymár, Hungary

G. Holló
Eye Center, Prima Medica Health Centers, Budapest, Hungary

Mean (SD) reduction from baseline at Month 6 for users of all latanoprost formulations (preserved and PF) was 6.1 (4.25) mmHg (25.9%; $p < 0.0001$).

The authors have also prepared a table to summarise the change in intraocular pressure following a switch to the preservative-free tafluprost/timolol fixed-dose combination from all latanoprost formulations (preserved and

Table 1 Change in intraocular pressure following a switch to the preservative-free tafluprost/timolol fixed-dose combination from all latanoprost formulations (preserved and preservative-free formulations)

Visit	N	Mean (SD) mmHg	Change from baseline, mean (SD) mmHg	Percentage of IOP reduction from baseline	p value*
<i>All latanoprost users (preserved and PF formulations)</i>					
Baseline	201	22.3 (4.93)			
Week 4	180	16.6 (3.43)	6.0 (4.16)	25.3	< 0.0001
Week 12	171	16.4 (3.16)	6.2 (4.43)	26.0	< 0.0001
Month 6	201	16.2 (3.30)	6.1 (4.25)	25.9	< 0.0001

IOP intraocular pressure, PF preservative-free, SD standard deviation.

*Two-sided paired t test for change in mean IOP from baseline to Weeks 4 and 12, and Month 6, respectively.

preservative-free formulations). See Table 1 below.

The original article has been corrected.

OPEN ACCESS

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.